(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue grew 23 percent to $1.15 billion from $938 million in the fourth quarter of 2009. For the year, revenue was $4.1 billion compared with $4.0 billion in 2009. Fourth-quarter revenue from the Personalized Genetic Health business grew 46 percent compared with the same period in 2009, and 26 percent from the third quarter of 2010. This growth reflects increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta), and the U.S. launch of Lumizyme® (alglucosidase alfa).
